StrongDecrease
Controlled attenuation parameter
Empagliflozin → Controlled attenuation parameter
Empagliflozin → Controlled attenuation parameter
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Empagliflozin and Pioglitazone improve heart function in diabetes patients
Key finding
GLS improved by 1.06 ± 1.83% (P < 0.01)
This study compared the effects of empagliflozin and pioglitazone on echocardiographic indices in patients with type 2 diabetes and nonalcoholic fatty liver disease, finding significant improvements in certain measures.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Some Concerns bias
Last updated July 6, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Empagliflozin, Pioglitazone
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
Global longitudinal strain
Comparator
Pioglitazone Group
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study compared the effects of empagliflozin and pioglitazone on echocardiographic indices in patients with type 2 diabetes and nonalcoholic fatty liver disease, finding significant improvements in certain measures.
Clinical relevance
These findings are significant as they suggest that both empagliflozin and pioglitazone can positively impact heart and liver health in patients with type 2 diabetes and nonalcoholic fatty liver disease. This could lead to better management of these conditions and improved patient outcomes.
Keep in mind
Limited sample size may affect generalizability. Short duration of follow-up may not capture long-term effects. Potential confounding factors not fully controlled.
Published in
Journal Reference
Publication details and source links for this paper.
Fereshte A, Sepideh E, Masoudreza S, et al. A Comparison between the Effect of Empagliflozin and Pioglitazone on Echocardiographic Indices in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. BMC Gastroenterology. 2023;23:327. doi:10.1186/s12876-023-02948-4
Save this study and add notes to your research library.
Main Effects
Empagliflozin improved global longitudinal strain by 1.06 ± 1.83% (P < 0.01).
Pioglitazone improved global longitudinal strain by 1.56 ± 2.34% (P < 0.01).
Controlled attenuation parameter improved by -48.22 ± 35.02 dB/m (P = 0.01) with empagliflozin.
Liver stiffness measure decreased significantly by -1.11 ± 1.33 kPa (P < 0.01) without substantial difference between groups.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Empagliflozin, Pioglitazone and Controlled attenuation parameter, Global longitudinal strain, Liver stiffness measure.
This study contributes evidence to
Primary intervention
Empagliflozin
Primary outcomes
- Controlled attenuation parameter
- Global longitudinal strain
- Liver stiffness measure
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 64
2
Related topics
6
Evidence pairs
22
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongIncrease
Global longitudinal strain
Empagliflozin → Global longitudinal strain
Empagliflozin → Global longitudinal strain
Evidence profile
StrongIncreaseClinical Outcomes
Unlock full evidence details
NoneDecrease
Liver stiffness measure
Empagliflozin → Liver stiffness measure
Empagliflozin → Liver stiffness measure
Evidence profile
NoneDecreaseClinical Outcomes
Unlock full evidence details
StrongDecrease
Controlled attenuation parameter
Pioglitazone → Controlled attenuation parameter
Pioglitazone → Controlled attenuation parameter
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
StrongIncrease
Global longitudinal strain
Pioglitazone → Global longitudinal strain
Pioglitazone → Global longitudinal strain
Evidence profile
StrongIncreaseClinical Outcomes
Unlock full evidence details
NoneDecrease
Liver stiffness measure
Pioglitazone → Liver stiffness measure
Pioglitazone → Liver stiffness measure
Evidence profile
NoneDecreaseClinical Outcomes
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Empagliflozin improved global longitudinal strain by 1.06%.
- Pioglitazone improved global longitudinal strain by 1.56%.
- Controlled attenuation parameter improved by -48.22 dB/m.
Who this applies to
- Adults with type 2 diabetes.
- Patients with nonalcoholic fatty liver disease.
Keep in Mind
- Results may not apply to populations outside the study group.
- Further research is needed to confirm long-term effects.
- The study did not account for all potential confounding variables.
Between the Lines
- Limited sample size may affect generalizability.
- Short duration of follow-up may not capture long-term effects.
- Potential confounding factors not fully controlled.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Controlled attenuation parameter, SGLT2 Inhibitors and Global longitudinal strain.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Controlled attenuation parameter Evidence Hub
All studies measuring Controlled attenuation parameter
1 studies
outcome_hubMeasures Controlled attenuation parameter as a key outcome.
Global longitudinal strain Evidence Hub
All studies measuring Global longitudinal strain
1 studies
outcome_hubMeasures Global longitudinal strain as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
1 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Empagliflozin and Controlled attenuation parameter
Intervention: EmpagliflozinOutcome: Controlled attenuation parameter
1 results
All studies on Empagliflozin and Global longitudinal strain
Intervention: EmpagliflozinOutcome: Global longitudinal strain
1 results
All studies on Empagliflozin
Intervention: Empagliflozin
1 results
All studies measuring Controlled attenuation parameter
Outcome: Controlled attenuation parameter
1 results
All studies measuring Global longitudinal strain
Outcome: Global longitudinal strain
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Empagliflozin improve controlled attenuation parameter?
Emerging Evidence
Empagliflozin appears to improve Controlled attenuation parameter.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Controlled attenuation parameter
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Empagliflozin improve global longitudinal strain?
Emerging Evidence
Empagliflozin appears to improve Global longitudinal strain.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Global longitudinal strain
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Pioglitazone improve controlled attenuation parameter?
Emerging Evidence
Pioglitazone appears to improve Controlled attenuation parameter.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Controlled attenuation parameter
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Pioglitazone improve global longitudinal strain?
Emerging Evidence
Pioglitazone appears to improve Global longitudinal strain.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Global longitudinal strain
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Empagliflozin improves heart function in type 2 diabetes patientsEmpagliflozin may improve nighttime blood sugar patterns in type 1 diabetesEmpagliflozin may reduce kidney disease biomarkers but shows mixed effects on albumin in early diabetesPioglitazone may reduce body fat inflammation in insulin resistanceEmpagliflozin reduces body fluid volume in type 2 diabetes patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.